Novel TGFBR2 and known missense SMAD3 mutations: two case reports of thoracic aortic aneurysms.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25555948.
- Also identified by DOI 10.1016/j.athoracsur.2014.02.068.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the clinical presentation and genetic screening of 2 patients with thoracic aortic aneurysms. A novel TGFBR2 mutation in the 5'untranslated region (c.-59C>T) was identified in a 31-year-old man with a Stanford type A aortic dissection. Bioinformatics tools showed that c.-59C>T variant was predicted to affect exonic splicing enhancer, as validated by quantitative real-time RT-PCR, revealing a sixfold increase of TGFBR2 mRNA in aneurysmal aortic tissue collected during surgery. A previously described missense mutation, p.E239K, in the SMAD3 gene was identified in a 60-year-old man who presented with diffuse vasculopathy. These findings suggest that the features of aneurysmal disease extending beyond the ascending aorta may help to target SMAD3 genetic screening and that alterations in the core splicing machinery can contribute to aneurysmal disease.
Medical subject headings
- Aortic Aneurysm, Thoracic
- Mutation
- Protein Serine-Threonine Kinases
- Receptors, Transforming Growth Factor beta
- Smad3 Protein